Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229124 | 1.00 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19154086 | 0.83 | KMT2A (0.39) | GAAKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL13368988 | 0.83 | DYRK1A (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3459253 | 0.81 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30548757 | 0.80 | CA1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4992020 | 0.80 | CA1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7121378 | 0.78 | CA1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20888466 | 0.77 | KMT2A (0.47) | HTTALDH1A1MEN1MAPTGFER | |
| SCHEMBL19011493 | 0.77 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29352597 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108863894-B | Method for directly synthesizing indole from nitrile | 中国科学技术大学 | 2020-08-14 | — | — | CN | claimed |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| US-10934486-B2 | Liquid crystal composition, liquid crystal mixture, reverse-mode polymer dispersed liquid crystal element, and associated selectively dimmable device | NITTO DENKO CORPORATION (JP) | 2021-03-02 | — | — | US | disclosed |
| EP-3239134-B1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2020-12-23 | — | — | EP | disclosed |
| CN-108863894-B | Method for directly synthesizing indole from nitrile | 中国科学技术大学 | 2020-08-14 | — | — | CN | disclosed |
| US-20190233728-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL MIXTURE, REVERSE-MODE POLYMER DISPERSED LIQUID CRYSTAL ELEMENT, AND ASSOCIATED SELECTIVELY DIMMABLE DEVICE | NITTO DENKO CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3067351-B1 | COMPOUND HAVING HIGHER INHIBITION OF PROTEIN KINASE G ACTIVITY AND PREPARATION METHOD THEREFOR | JENKEM TECH CO LTD TIANJIN (CN) | 2019-02-06 | — | — | EP | disclosed |
| WO-2018068023-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL MIXTURE, REVERSE-MODE POLYMER DISPERSED LIQUID CRYSTAL ELEMENT, AND ASSOCIATED SELECTIVELY DIMMABLE DEVICE | NITTO DENKO CORPORATION (JP) | 2018-04-12 | — | — | WO | disclosed |
| US-9925171-B2 | Compound having higher inhibitory activity on protein kinase G and preparation method thereof | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2018-03-27 | — | — | US | disclosed |
| EP-3239134-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2311455-B1 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS INC (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-2301538-B1 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-7732463-B2 | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2010-06-08 | — | — | US | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | H.LUNDBECK A/S (DK) | 2006-05-11 | — | — | US | disclosed |
| EP-1626720-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004087156-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
| EP-0572986-B1 | Assay for serum cholinesterase | JOHNSON & JOHNSON CLIN DIAG (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0572986-A1 | Assay for serum cholinesterase | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1993-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | HTR4, HTR5A, TPH1 | CA12 3931/4885CA1 2829/4885CA2 3285/4885 |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 4857/4885CA1 4522/4885CA2 4080/4885 |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | CA12 4671/4885CA1 4813/4885CA2 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.